About: SP600125 inhibits Orthopoxviruses replication in a JNK1/2 -independent manner: Implication as a potential antipoxviral

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SP600125 inhibits Orthopoxviruses replication in a JNK1/2 -independent manner: Implication as a potential antipoxviral Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SP600125 inhibits Orthopoxviruses replication in a JNK1/2 -independent manner: Implication as a potential antipoxviral
Creator	Souto-Padrón, Thais Soares-Martins, Jamária Bonjardim, Cláudio Da Cruz, André Ferreira, Paulo Kroon, Erna Leite, Flávia Pereira, Anna Torres, Alice
Source	Elsevier; Medline; PMC
abstract	Abstract The pharmacological inhibitor SP600125 [anthra(1,9-cd)pyrazol-6(2H)-one 1,9-pyrazoloanthrone] has been largely employed as a c-JUN N-terminal kinase (JNK1/2) inhibitor. In this study, we evaluated whether pretreatment with SP600125 was able to prevent Orthopoxviruses Vaccinia virus (VACV), Cowpox virus (CPXV) and modified Vaccinia virus Ankara (MVA) replication. We found that incubation with SP600125 not only blocked virus-stimulated JNK phosphorylation, but also, significantly reduced virus production. We observed 1–3 log decline in viral yield depending on the cell line infected (A31, BSC-40 or BHK-21). The reduction in viral yield correlated with a dramatic impact on virus morphogenesis progress, intracellular mature viruses (IMV) were barely detected. Despite the fact that SP600125 can act as an efficient anti-orthopoxviral compound, we also provide evidence that this antiviral effect is not specifically exerted through JNK1/2 inhibition. This conclusion is supported by the fact that viral titers measured after infections of JNK1/2 knockout cells were not altered as compared to those of wild-type cells. In contrast, a decline in viral titers was verified when the infection of KO cells was carried out in the presence of the pharmacological inhibitor. SP600125 has been the focus of recent studies that have evaluated its action on diverse viral infections including DNA viruses. Our data support the notion that SP600125 can be regarded as a potential antipoxviral compound.
has issue date	2012-01-31(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2011.10.020
bibo:pmid	22068148
has license	els-covid
sha1sum (hex)	a509eb52e4cd3d77cd7eb1d62d697286fd2d3a98
schema:url	https://doi.org/10.1016/j.antiviral.2011.10.020
resource representing a document's title	SP600125 inhibits Orthopoxviruses replication in a JNK1/2 -independent manner: Implication as a potential antipoxviral
has PubMed Central identifier	PMC7114308
has PubMed identifier	22068148
schema:publication	Antiviral Research
resource representing a document's body	covid:a509eb52e4cd3d77cd7eb1d62d697286fd2d3a98#body_text
is schema:about of	named entity 'ORTHOPOXVIRUSES' named entity 'altered' named entity 'carried' named entity 'viruses' named entity 'Vaccinia virus' named entity 'Ankara' named entity 'reduced' named entity 'viral' named entity 'titers' named entity 'blocked' named entity 'Despite' named entity 'evaluated' named entity '1-3' named entity 'MODIFIED' named entity 'DATA' named entity 'POTENTIAL' named entity 'CORRELATED' named entity 'STUDIES' named entity 'NOTION' named entity 'EMPLOYED' named entity 'STIMULATED' named entity 'INFECTION' named entity 'INHIBITOR' named entity 'JNK' named entity 'CELL LINE' named entity 'VIRAL' named entity 'REDUCTION' named entity 'INFECTED' named entity 'VERIFIED' named entity 'RECENT' named entity 'FOUND' named entity 'STUDY' named entity 'SUPPORTED' named entity 'FACT' named entity 'COMPARED' named entity 'COWPOX VIRUS' named entity 'ACTION' named entity 'HAVE' named entity 'OUR' named entity 'REPLICATION' named entity 'VIRUS PRODUCTION' named entity 'BUT' named entity 'IMPACT' named entity 'DNA VIRUSES' named entity 'PHOSPHORYLATION' named entity 'MATURE' named entity 'EFFECT' named entity 'INFECTIONS' named entity 'EXERTED' named entity 'INCLUDING' named entity 'LARGELY' named entity 'CARRIED' named entity 'OBSERVED' named entity 'DECLINE' named entity 'ALTERED' named entity 'REDUCED' named entity 'PROGRESS' named entity 'MEASURED' named entity 'VIRUS' named entity 'VACCINIA VIRUS ANKARA' named entity 'KNOCKOUT' named entity 'PRESENCE OF' named entity 'PRETREATMENT' named entity 'THE CELL' named entity 'WILD-TYPE' named entity 'BSC' named entity 'SUPPORT' named entity 'DIVERSE' named entity 'FOCUS' named entity 'BHK-21' named entity 'CONTRAST' named entity 'C-JUN N-TERMINAL KINASE' named entity 'CONCLUSION'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software